IL6 and COVID-19: Notably, expression of interleukin (IL)-6 was unchanged in the lungs of patients with COVID-19 (SI Appendix, Fig. S1), a finding that raises a question about the potential for anti-IL-6 therapy to help resolve the pulmonary inflammatory process in patients with severe disease.